<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042822</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069473</org_study_id>
    <secondary_id>MSKCC-00116</secondary_id>
    <secondary_id>NCI-1715</secondary_id>
    <nct_id>NCT00042822</nct_id>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have&#xD;
      myelodysplastic syndrome, acute myeloid leukemia, or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the pattern of adverse clinical experience in patients with myelodysplastic&#xD;
           syndrome, acute myeloid leukemia, or intermediate-grade or follicular non-Hodgkin's&#xD;
           lymphoma treated with FR901228 (depsipeptide).&#xD;
&#xD;
        -  Determine the disease response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetic and pharmacodynamic correlates of this drug, including&#xD;
           measurement of serum plasma levels, H3 and H4 acetylation, apoptosis induction,&#xD;
           differentiation, and multidrug-resistant (MDR) phenotype expression in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1 and 5. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed monthly.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically confirmed refractory or relapsed acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  Failed anthracycline-based chemotherapy&#xD;
&#xD;
                    -  Ineligible for or refused allogeneic stem cell transplantation&#xD;
&#xD;
               -  Elderly patients with newly diagnosed AML&#xD;
&#xD;
                    -  Ineligible for or refused standard chemotherapy&#xD;
&#xD;
               -  Histologically confirmed high-risk myelodysplastic syndromes&#xD;
&#xD;
                    -  Eligible subtypes include:&#xD;
&#xD;
                         -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                         -  RAEB in transformation&#xD;
&#xD;
                         -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Ineligible for or refused allogeneic bone marrow transplantation&#xD;
&#xD;
               -  Histologically confirmed intermediate-grade non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Relapsed after high-dose therapy OR&#xD;
&#xD;
                    -  Ineligible for allogeneic or autologous stem cell transplantation&#xD;
&#xD;
                    -  Evaluable lesions by radiologic study or physical examination&#xD;
&#xD;
               -  Histologically confirmed follicular NHL&#xD;
&#xD;
                    -  Progressed after anthracycline-based chemotherapy and rituximab&#xD;
&#xD;
                    -  Evaluable lesions by radiologic study or physical examination NOTE: A new&#xD;
                       classification scheme for adult non-Hodgkin's lymphoma has been adopted by&#xD;
                       PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the&#xD;
                       former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma.&#xD;
                       However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's syndrome)&#xD;
&#xD;
          -  SGOT and SGPT less than 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction greater than 50%&#xD;
&#xD;
          -  No cardiac hypertrophy&#xD;
&#xD;
          -  No known conduction heart disease&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease that would make it&#xD;
             difficult to assess patient during study participation&#xD;
&#xD;
          -  No significant prior heart disease&#xD;
&#xD;
          -  No significant prior secondary or tertiary heart block&#xD;
&#xD;
          -  No significant prior atrial or ventricular arrhythmia requiring therapeutic&#xD;
             intervention or antiarrhythmics for rate control&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe debilitating pulmonary disease that would make it difficult to assess&#xD;
             patient during study participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  Potassium ≥ 4.0 mmol/L (supplementation allowed)&#xD;
&#xD;
          -  Magnesium ≥ 2.0 mg/dL (supplementation allowed)&#xD;
&#xD;
          -  No other concurrent active malignancy except basal cell skin cancer&#xD;
&#xD;
          -  No other concurrent significant co-morbidity that would make it difficult to assess&#xD;
             patient during study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior epoetin alfa or filgrastim (G-CSF)&#xD;
&#xD;
          -  At least 4 weeks since prior cytokines&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent drugs that may prolong the QTc interval&#xD;
&#xD;
               -  FR901228 (depsipeptide) may be administered after a 5-half-life washout period&#xD;
                  following the use of these drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Klimek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.</citation>
    <PMID>18245545</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2011</last_update_submitted>
  <last_update_submitted_qc>May 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

